Table 1.
Clinical and laboratorial characteristics of HIV-1 co-infected leishmaniasis patients and control groups.
| Parameters | AVL/HIV-1 patients (n = 9) |
ATL/HIV-1 patients (n = 8) |
HIV-1 infected* (n = 16) |
Healthy subjects (n = 8) |
|---|---|---|---|---|
| Age, years, (median) | 38 (35-50)a | 44 (38-54)b | 39 (33-49)c | 26 (25-30)abc |
| Male sex, n, (%) | 9 (100)d | 8 (100)e | 15 (94)f | 4 (50)def |
| CD4+T Cell count, cells/mm3 | 62 (52-127)g | 404 (294-597)h | 380 (223-450)i | 1,106 (957-1,300)ghi |
| Current AIDS diagnosis, Number of cases (%) | 9 (100) | 6 (75) | 8 (50) | ---- |
| Time of clinical remission of leishmaniasis, months | 8 (6-12) | 11 (7.5-14) | ---- | ---- |
| Patients with undetectable viremia, (%) | 5 (55.6) | 4 (50) | 9 (56.2) | ---- |
| Viral load levels of patients with detectable viremia, copies/mL | 142,240 (24,025-279,321) | 6,200 (2,012-78,176) | 12,010 (2,000-136,625) | ---- |
N = number, AVL - American visceral leishmaniasis, ATL - American tegumentary leishmaniasis *HIV-1 infected patients without leishmaniasis Note: Data are median (interquartile range) values, except for current AIDS diagnosis.
Patients × Health subjects (a - p < 0.001; b/c - p < 0.01; d/e/f × def - p < 0.05), g/h/i × ghi - p < 0.001; g × h - p < 0.01; g × i - p < 0.01